Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours

Document Type : Original Article


1 Ascend Technologies Ltd, Eastleigh, UK

2 Faculty of Civil Engineering, University of Belgrade, Belgrade, Serbia

3 Institute of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria


Objective(s): The objectives of this work was to assess the benefits of the application of Physiologically Based Pharmacokinetic (PBPK) models in patients with different neuroendocrine tumours (NET) who were treated
with Lu-177 DOTATATE. The model utilises clinical data on biodistribution of radiolabeled peptides (RLPs) obtained by whole body scintigraphy (WBS) of the patients.
Methods: The blood flow restricted (perfusion rate limited) type of the PBPK model for biodistribution of radiolabeled peptides (RLPs) in individual human organs is based on the multi-compartment approach, which takes into account the main physiological processes in the organism: absorption, distribution, metabolism and excretion (ADME). The approach
calibrates the PBPK model for each patient in order to increase the accuracy of the dose estimation. Datasets obtained using WBS in four patients have been used to obtain the unknown model parameters. The scintigraphic data were acquired using a double head gamma camera in patients with different neuroendocrine tumours who were treated with Lu-177 DOTATATE. The activity administered to each patient was 7400MBq.
Results: Satisfactory agreement of the model predictions with the data obtained from the WBS for each patient has been achieved. Conclusion: The study indicates that the PBPK model can be used for more accurate calculation of biodistribution and absorbed doses in patients. This approach is the first attempt of utilizing scintigraphic data in PBPK models, which was obtained during Lu-177 peptide therapy of patients with NET.


Main Subjects

1. Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett. 2003;138(1- 2):29-49.
2. Lee HA, Leavens TL, Mason SE, Monteiro- Riviere NA, Riviere JE. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett. 2009;9(2):794-9.
3. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55(20):4611-22.
4. Baxter LT, Zhu H, Mackensen DG, Jain RK. physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517-28.
5. Adams JC, Dills RL, Morgan MS, Kalman DA, Pierce CH. A physiologically based toxicokinetic model of inhalation exposure to xylenes in Caucasian men. Regul Toxicol Pharmacol. 2005;43(2):203-14.
6. Van Asperen J, Rijcken WR, Lammers JH. Application of physiologically based toxicokinetic modelling to study the impact of the exposure scenario on the toxicokinetics and the behavioural effects of toluene in rats. Toxicol Lett. 2003;138(1-2):51-62.
7. Sweeney LM, Gut CP Jr, Gargas ML, Reddy G, Williams LR, Johnson MS. Assessing the non-cancer risk for RDX (hexahydro-1,3,5-trinitro- 1,3,5-triazine) using physiologically based pharmacokinetic (PBTK) modelling. Regul Toxicol Pharmacol. 2012;62(1):107-14.
8. Krishnan K, Peyret T. Physiologically based toxicokinetic (PBTK) modeling in ecotoxicology. InEcotoxicology modelingmodelling. New York: Springer; 2009. (ppP. 145-175). Springer US
9. Clewell RA, Clewell HJ 3rd. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol. 2008;50(1):129-43.
10. Nestorov I. Whole-Body Physiologically Based Pharmacokinetic Models. Expert Opin Drug Metab Toxicol. 2007;3(2):235-49.
11. Ings RM. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica. 1990;20(11):1201–31.
12. Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5-19.
13. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(Suppl 1):99S-106S.
14. Lassmann M, Chiesa C, Flux G, Bardiès M, EANM Dosimetry Committee. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38(1):192-200.
15. 1990 Recommendations of the International Commission on Radiological Protection.. Ann ICRP. 1991;21(1-3):1-201.
16. Yamashita F, Hashida M. Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev. 2013;65(1):139-47.
17. Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med. 2008;49(5):853-60.
18. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modelling: principles and applications. J Pharm Sci. 1983;72(10):1103-27.
19. Davies B, Morris T. Physiological Parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-5.
20. Broyden CG. Quasi-Newton methods and their application to function minimization. Maths Comput. 1967;21(99):368-81.
21. Fletcher R. A new approach to variable metric algorithms. Computer J. 1970;13(3):317-22.
22. Goldfarb D. A family of variable-metric methods derived by variational means. Maths Comput. 1970;24(109):23-26.
23. Shanno DF. Conditioning of quasi-Newton methods for function minimization. Maths Comput. 1970; 24(111):647-56.
24. Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Oncology. 2011;80(5-6):326-9.
25. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9-15.
26. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51(7):1049-58.
27. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124-30.
28. Reddy M, Yang RS, Andersen ME, Clewell III III HJ. Physiologically based pharmacokinetic modeling: science and application. Hoboken, New Jersey: John Wiley & Sons; 2005.
29. Ball R, Schwartz SL. CMATRIX: software for physiologically based pharmacokinetic modeling using a symbolic matrix representation system. Comput Biol Med. 1994;24(4):269-76.
30. Lin JH, Sugiyama Y, Awazu S, Hanano M. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm. 1982; 10(6): 637-47.
31. Hissink AM, Wormhoudt LW, Sherratt PJ, Hayes JD, Commandeur JN, Vermeulen NP, et al. A physiologically-based pharmacokinetic (PB-PK) model for ethylene dibromide: relevance of extrahepatic metabolism. Food Chem Toxicol. 2000;38(8):707-16.
32. Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol. 1999;5(6):556-69.
33. Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol. 1999;5(6):538-55.
34. Lueshen E, Hall C, Mošat A, Linninger A. Physiologically-Based Pharmacokinetic Modeling: Parameter Estimation for Cyclosporin A. In: Pistikopoulos EN, Georgiadis MC, Kokossis AC, editors. 21st European Symposium on Computer Aided Process Engineering. 1st ed. Philadelphia: Elsevier; 2011. P. 1543.
35. Toint PL. Toint PL. Global convergence of aa of trust-region methods for nonconvex minimization in hilbert space. IMA J Numerical Anal. 1988;8(2):231- 52.
36. Nocedal J, Wright S. Numerical optimization. 2nd ed. New York: Springer Science & Business Media; 2006.
37. Conn AR, Gould NI, Toint PL. Trust-region methods, society for industrial and applied mathematics. SIAM, Philadelphia. 2000;1(7):12.